Guidant Atherocath shows 32% restenosis at six months -- preliminary BOAT study results.
This article was originally published in The Gray Sheet
Executive Summary
GUIDANT ATHEROCATH 32% SIX-MONTH RESTENOSIS RATE shown in preliminary results of the 1,000-patient Balloon versus Optimal Atherectomy Trial (BOAT), which were presented Aug. 26 at the European Society of Cardiology meetings in Birmingham, England. Patients with coronary artery disease treated via an "optimal" method with the Atherocath directional coronary atherectomy device showed a 20% reduction in restenosis compared to patients treated with percutaneous transluminal coronary angioplasty alone.